Navigation Links
New PICC Mimics Nature
Date:7/1/2009

A novel coating being used on a new peripherally inserted central catheter (PICC) from r4 Vascular mimics the cell layer found on natural tissue surfaces. r4 Vascular designed the catheter to have a biomimetic surface that mimics the natural glycocalyx layer on endothelial tissues.

Maple Grove, MN (Vocus) July 1, 2009 -- A novel coating being used on a new peripherally inserted central catheter (PICC) from r4 Vascular mimics the cell layer found on natural tissue surfaces. r4 Vascular designed the catheter to have a biomimetic surface that mimics the natural glycocalyx layer on endothelial tissues. Laboratory tests prove that mimicking the glycocalyx layer can dramatically reduce thrombus formation on the catheter surfaces.

r4 Vascular recently gained FDA clearance to launch their first catheter based on this Biomimetic technology. It will be available beginning June 30, 2009 as the Zeus™ Coated CT PICC.

According to Gail Sansivero, MS, ANP, Vascular and Interventional Radiology Nurse Practitioner, Albany Medical Center, "Thrombus can be a real problem for patients with PICCs. Biologically, a patient responds to a catheter insertion within 24 hours by developing bio-film. Thrombus can later amass on the catheter surface, within the catheter and/or become adherent to the vein. The thrombus can cause catheter occlusion, serve as a nidus for infection, and even dislodge into the bloodstream, putting patients at risk for deep vein thrombosis (DVT) or pulmonary embolism (PE)."

Today, clinicians typically try to avoid thrombus occlusion by instilling heparin into catheters between uses. However, many patients are allergic to heparin, which can cause heparin-induced thrombocytopenia (HIT). Some PICC manufacturers have addressed the thrombus problem by affixing valves to their catheters, which can limit placement methods and reliable blood sample withdrawal through the catheter. r4 Vascular engineers took a cue from stealth technologies instead, approaching the problem by camouflaging the catheter in a Biomimetic coating. Laboratory testing has shown the coating to be so effective that it is the first nonvalved PICC to receive FDA clearance for saline-only maintenance.

According to r4 Vascular's CEO, Michael Sarajian, "In speaking with PICC clinicians, we learned that valved PICCs can be difficult to place and unreliable in use. By approaching the thrombus problem scientifically, r4 has developed a nonvalved PICC that enables over-the-wire placement and reliable blood draws while reducing thrombus formation for a longer service life."

r4 Vascular is a privately-held vascular access company driving innovation in vascular access medical technology. r4's passion is "uncomplicating" venous access, chemotherapy, and drug delivery, through product improvements that help catheters remain patent and effective, with reduced risk of complications.

John Zawacki
r4 Vascular, Inc.
763-494-8400
Fax: 763-494-8484
www.r4vascular.com

###

Read the full story at http://www.prweb.com/releases/r4_Vascular/biomimetic/prweb2596764.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Lab on a chip mimics brain chemistry
2. Virus mimics human protein to hijack cell division machinery
3. Yeast mimics severity of mutations leading to fatal childhood illness
4. Gene signature spells poor outcome
5. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
6. Revealing the workings of Mother Natures blowtorch
7. APHA Urges President Bush Not To Veto CHIP; Were Only One Signature Away from Protecting the Health of Our Children
8. DuPont Pledges $250,000 to Nature Conservancy for Water Quality Initiative
9. Natures Baby Organics Announces Ah-Choo! Chest Rub
10. National Nature Made(R) Survey Finds U.S. Adults Are Concerned About Heart Disease but May not be Managing Their Risk
11. New neuroimaging study identifies brain signature for cigarette cravings
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New PICC Mimics Nature
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Chester County, a Property owned by an affiliate of Seavest, has won a ... Penn Medicine Southern Chester County ambulatory care center (ACC) was named “Best New ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the ... advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat lung cancer, ... Michael J. Hennessy, Jr said, “CURE Media Group is honored to team up with ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , Ginger Pigott ... LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont Newport Beach ... from the firm’s global Life Sciences & Medical Technology Group have been featured speakers ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView Software aims to redefine ... are both engaging and easy to use. Coming off the heels of a ... today its plans to roll out new AI-powered self-service enhancements to help organizations ...
(Date:12/8/2016)... Somerset, N.J. (PRWEB) , ... December 08, 2016 ... ... advanced delivery technologies and development solutions for drugs, biologics and consumer health products, ... The PSCI was set up in 2006 as a non-profit organization to unite ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Dec 9, 2016 Research and Markets has announced ... Business Report" report to their offering. ... The report also analyses the market by the following ... comprehensive analytics for the US, Canada , ... , Latin America , and Rest of World. ...
(Date:12/9/2016)... Dec. 9, 2016 aTyr Pharma, Inc. (Nasdaq: ... of Physiocrine-based therapeutics to address severe, rare diseases, today announced that ... BMO Prescriptions for Success Healthcare Conference at the InterContinental Barclay Hotel ... 14, 2016, at 4:20 p.m. ET. About aTyr ... aTyr ...
(Date:12/9/2016)... DIEGO , Dec. 9, 2016  Forge ... Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: ... targeting ,LpxC, for the treatment of bacterial infections ... has been recognized as an attractive antibacterial target ... a lack of suitable chemical starting points has ...
Breaking Medicine Technology: